VX-745|2mg|K1299-上海高创化学科技有限公司

SKU:K1299		M. Wt:436.26
Formula:C19H9Cl2F2N3OS		Solubility:No
Purity:>99%		Storage:2 years -20°C Powder
CAS No.:209410-46-8		Synonyms:N/A
Chemical NameN/A

Description	VX-745
Targets	p38-alpha MAPK	p38-beta MAPK
IC50	10 nM	220 nM
In vitro	VX-745,a lead anti-inflammatory candidate, is a small-molecule inhibitor of mitogen-activated protein kinase (MAPK). VX-745 inhibits interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) secretion in bone marrow stromal cells (BMSCs), without affecting their viability. VX-745 can also inhibit tumor necrosis factor alpha (TNF-alpha)-induced IL-6 secretion in BMSCs. VX-745 inhibits both MM cell proliferation and IL-6 secretion in BMSCs triggered by adherence of MM cells to BMSCs. VX-745 can inhibit paracrine MM cell growth in the BM milieu and overcome cell adhesion-related drug resistance. VX-745 potently inhibited TNF release from LPS stimulated human THP-1 cells with IC50s of 29 nM.
In vivo	VX-745 is effective against adjuvant-induced arthritis (AA) in the rat with ED50 of 5 mg/kg. Histological scores for VX-745 in AA rats are 93% inhibition of bone resorption and 56% inhibition of inflammation.
Clinical Trials	N/A
Features	N/A

Description

VX-745

Targets

p38-alpha MAPK

p38-beta MAPK

IC50

10 nM

220 nM

In vitro

VX-745,a lead anti-inflammatory candidate, is a small-molecule inhibitor of mitogen-activated protein kinase (MAPK). VX-745 inhibits interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) secretion in bone marrow stromal cells (BMSCs), without affecting their viability. VX-745 can also inhibit tumor necrosis factor alpha (TNF-alpha)-induced IL-6 secretion in BMSCs. VX-745 inhibits both MM cell proliferation and IL-6 secretion in BMSCs triggered by adherence of MM cells to BMSCs. VX-745 can inhibit paracrine MM cell growth in the BM milieu and overcome cell adhesion-related drug resistance. VX-745 potently inhibited TNF release from LPS stimulated human THP-1 cells with IC50s of 29 nM.

In vivo

VX-745 is effective against adjuvant-induced arthritis (AA) in the rat with ED50 of 5 mg/kg. Histological scores for VX-745 in AA rats are 93% inhibition of bone resorption and 56% inhibition of inflammation.

Clinical Trials

N/A

Features

N/A

工商信息

企业名称

上海高创化学科技有限公司

企业信息已认证

企业类型

信用代码

310228001353263

成立日期

2010-06-05

注册资本

经营范围

从事化学科技、计算机领域内技术开发、技术咨询、技术服务,从事生物科技领域内技术开发、技术咨询,化学试剂、化工原料及产品(除危险化学品、监控化学品、烟花爆竹、民用爆炸物品、易制毒化学品),实验室设备(除医疗器械),仪器仪表,Ⅰ类医疗器械,金属制品,电子产品,机电产品销售。【依法须经批准的项目,经相关部门批准后方可开展经营活动】

VX-745由上海高创化学科技有限公司为您提供，货号K1299，规格：2mg，CAS号：209410-46-8，如您想了解更多关于VX-745价格、VX-745结构式、批发、用途等信息，欢迎咨询。除供应VX-745外，还可为您提供特级新生牛血清（无支原体）、重组人心肌营养素1/CTF1 Human、Gibco山羊血清（新西兰）等试剂，公司有专业的客户服务团队，是您值得信赖的合作伙伴，上海高创客户服务电话，售前、售后均可联系。